Express Pharma

C2 PHARMA opens research access to safety stock of Digoxin API for use in potential COVID-19 combination treatment

Digoxin is extracted from the digitalis lanata plant. Due to the structure of the ingredient, it cannot be manufactured synthetically, so there is no way for API manufacturers to respond quickly to demand peaks